Next Article in Journal
Protective Effects of Euphrasia officinalis Extract against Ultraviolet B-Induced Photoaging in Normal Human Dermal Fibroblasts
Next Article in Special Issue
Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells
Previous Article in Journal
Integrated Analysis of Transcriptomic and Proteomics Data Reveals the Induction Effects of Rotenoid Biosynthesis of Mirabilis himalaica Caused by UV-B Radiation
Previous Article in Special Issue
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Receptor-Targeted Glial Brain Tumor Therapies

Brain Tumor Center of Excellence, Department of Cancer Biology, Wake Forest University School of Medicine, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(11), 3326; https://doi.org/10.3390/ijms19113326
Submission received: 25 September 2018 / Revised: 16 October 2018 / Accepted: 19 October 2018 / Published: 25 October 2018
(This article belongs to the Special Issue Receptor-Targeted Cancer Therapy)

Abstract

Among primary brain tumors, malignant gliomas are notably difficult to manage. The higher-grade tumors represent an unmet need in medicine. There have been extensive efforts to implement receptor-targeted therapeutic approaches directed against gliomas. These approaches include immunotherapies, such as vaccines, adoptive immunotherapy, and passive immunotherapy. Targeted cytotoxic radio energy and pro-drug activation have been designed specifically for brain tumors. The field of targeting through receptors progressed significantly with the discovery of an interleukin 13 receptor alpha 2 (IL-13RA2) as a tumor-associated receptor over-expressed in most patients with glioblastoma (GBM) but not in normal brain. IL-13RA2 has been exploited in novel experimental therapies with very encouraging clinical responses. Other receptors are specifically over-expressed in many patients with GBM, such as EphA2 and EphA3 receptors, among others. These findings are important in view of the heterogeneity of GBM tumors and multiple tumor compartments responsible for tumor progression and resistance to therapies. The combined targeting of multiple receptors in different tumor compartments should be a preferred way to design novel receptor-targeted therapeutic approaches in gliomas.
Keywords: Glioblastoma; IL-13RA2; targeted therapies; tumor-associated receptor; peptide vaccines; dendritic cell-based vaccines; CAR T-cell therapy; eph/ephrin receptor system; EGFR/EGF receptor system; immune checkpoint inhibitors; viral/genetic therapies Glioblastoma; IL-13RA2; targeted therapies; tumor-associated receptor; peptide vaccines; dendritic cell-based vaccines; CAR T-cell therapy; eph/ephrin receptor system; EGFR/EGF receptor system; immune checkpoint inhibitors; viral/genetic therapies
Graphical Abstract

Share and Cite

MDPI and ACS Style

Sharma, P.; Debinski, W. Receptor-Targeted Glial Brain Tumor Therapies. Int. J. Mol. Sci. 2018, 19, 3326. https://doi.org/10.3390/ijms19113326

AMA Style

Sharma P, Debinski W. Receptor-Targeted Glial Brain Tumor Therapies. International Journal of Molecular Sciences. 2018; 19(11):3326. https://doi.org/10.3390/ijms19113326

Chicago/Turabian Style

Sharma, Puja, and Waldemar Debinski. 2018. "Receptor-Targeted Glial Brain Tumor Therapies" International Journal of Molecular Sciences 19, no. 11: 3326. https://doi.org/10.3390/ijms19113326

APA Style

Sharma, P., & Debinski, W. (2018). Receptor-Targeted Glial Brain Tumor Therapies. International Journal of Molecular Sciences, 19(11), 3326. https://doi.org/10.3390/ijms19113326

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop